EUVIMEDEUVIMED entdecken
Crossref

The Price of EpiPens: A Matter of Life and Death

Andi Bettinger

Law, History, and Society · 05.01.2025 · 2 (1)

DOI: 10.32473/lhs.2.1.137384 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Law, History, and Society, online erschienen am 05.01.2025. Verfasst von Andi Bettinger.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This article examines how the EpiPen achieved market dominance through patent extensions to stifle competition, strategic lobbying efforts, drug misclassification, price hikes, and other ethically questionable practices in the pharmaceutical industry. Despite facing significant public backlash and legal action for its practices, Mylan capitalized on regulatory gaps, weak enforcement, and the government’s delayed response to anticompetitive behavior. These systemic failures enabled the company to exploit its near-monopoly on life-saving medicines like the EpiPen. By examining corporate misconduct and governmental oversight shortcomings, this analysis reveals the intricate relationship between profit-driven pharmaceutical strategies and systemic flaws in healthcare regulation, uncovering the industry's broader challenges.

Zitieren

APA

Bettinger, A. (2025). The Price of EpiPens: A Matter of Life and Death. Law, History, and Society, 2(1). https://doi.org/10.32473/lhs.2.1.137384

Vancouver

Bettinger A. The Price of EpiPens: A Matter of Life and Death. Law, History, and Society. 2025;2(1). doi:10.32473/lhs.2.1.137384

BibTeX
@article{Bettinger2025,
  author = {Bettinger, Andi},
  title = {The Price of EpiPens: A Matter of Life and Death},
  journal = {Law, History, and Society},
  year = {2025},
  volume = {2},
  number = {1},
  doi = {10.32473/lhs.2.1.137384}
}
Kostenlos starten →